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Background
Since 2004, the HIV Vaccines and Microbicides Resource
Tracking Working Group has employed a comprehensive
methodology to track trends in R&D investments and
expenditures for biomedical HIV prevention options,
including HIV vaccines, microbicides, pre-exposure pro-
phylaxis (PrEP), treatment as prevention, adult voluntary
medical male circumcision, female condoms, HSV-2 pre-
vention and vertical transmission prevention. Such moni-
toring is critical to identifying trends in investment and
providing a fact base for policy advocacy on R&D spend-
ing levels and allocations.
Methods
To estimate annual investment in HIV vaccine R&D, data
were collected from government agencies, nonprofit
research organizations, foundations and pharmaceutical/
biotechnology companies on annual disbursements for
product development, clinical trials and trial preparation,
community education and policy advocacy efforts.
Results
Preliminary estimates suggest that public and philanthro-
pic funding for HIV vaccine research has been experien-
cing increased stress. As funding priorities shifted within
governments and major donors revised their R&D grant
strategies, disbursements for research in 2011 were often
flat-lined or decreased. While the biotechnology industry
continued their R&D efforts, companies increasingly
focused on forming product development partnerships to
ensure future funding and relied on grants from public
sector sources to continue their clinical trials.
Conclusion
2011 saw continued progress toward the development of a
safe and effective HIV vaccine. With the discovery of anti-
bodies predicting the risk of HIV infection, the start of
large-scale follow-on trials and the initiation of HIV vac-
cine R&D programs in more countries around the world,
there has been real progress on the path from research to
reality. However, funding to pursue all this promise is
highly uncertain. Sustained resources will be essential to
assure that trials now underway can proceed, and
increased expenditures will be similarly essential for the
successive clinical phases of the most promising vaccine
candidates.
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